These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1084968)

  • 1. Beneficial effects of serotonin precursors in postanoxic action myoclonus.
    De Léan J; Richardson JC; Hornykiewicz O
    Neurology; 1976 Sep; 26(9):863-8. PubMed ID: 1084968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486.
    Van Woert MH; Sethy VH
    Neurology; 1975 Feb; 25(2):135-40. PubMed ID: 1078720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemistry and therapeutics of posthypoxic myoclonus.
    Van Woert MH; Rosenbaum D; Chung EY
    Adv Neurol; 1986; 43():171-81. PubMed ID: 2418644
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathological findings in a case of hypoxic myoclonus treated with 5-hydroxytryptophan and a decarboxylase inhibitor.
    De Léan J; Richardson JC; Rewcastle NB
    Adv Neurol; 1986; 43():215-23. PubMed ID: 2418647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.
    Chadwick D; Hallett M; Harris R; Jenner P; Reynolds EH; Marsden CD
    Brain; 1977 Sep; 100(3):455-87. PubMed ID: 412560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical, biochemical, and pharmacological observation in a patient with postasphyxic myoclonus: association to serotonin hyperactivity.
    Giménez-Roldán S; Mateo D; Muradas V; De Yebenes JG
    Clin Neuropharmacol; 1988 Apr; 11(2):151-60. PubMed ID: 2454156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin and myoclonus.
    Van Woert MH; Jutkowitz R; Rosenbaum D; Bowers MB
    Monogr Neural Sci; 1976; 3():71-80. PubMed ID: 790170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
    N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of posthypoxic action myoclonus: implications for the pathophysiology of the disorder.
    Chadwick D; Hallett M; Jenner P; Marsden CD
    Adv Neurol; 1986; 43():183-90. PubMed ID: 2418645
    [No Abstract]   [Full Text] [Related]  

  • 10. Postanoxic myoclonus. Treatment of a case with 5-hydroxytryptophane and a decarboxylase inhibitor.
    Beretta E; Regli F; de Crousaz G; Steck AJ
    J Neurol; 1981; 225(1):57-62. PubMed ID: 6164757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter: Treatment of post-anoxic intention myoclonus.
    Van Woert MH; Sethy VH
    Lancet; 1974 Jun; 1(7869):1285. PubMed ID: 4134164
    [No Abstract]   [Full Text] [Related]  

  • 12. Post-hypoxic intention myoclonus treated with 5-hydroxy-tryptophan and an extracerebral decarboxylase inhibitor.
    Magnussen I; Dupont E; Engbaek F; de Fine Olivarius B
    Acta Neurol Scand; 1978 Apr; 57(4):289-94. PubMed ID: 307327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine in the treatment of intention myoclonus.
    Van Woert MH; Magnussen I; Rosenbaum D; Chung E
    Clin Neuropharmacol; 1983 Mar; 6(1):49-54. PubMed ID: 6189599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa.
    Thal L; Sharpless N; Wolfson L; Engel J; Katzman R
    Trans Am Neurol Assoc; 1976; 101():48-52. PubMed ID: 1088459
    [No Abstract]   [Full Text] [Related]  

  • 15. Manipulation of brain serotonin in the treatment of myoclonus.
    Chadwick D; Jenner P; Harris R; Reynolds EH; Marsden CD
    Lancet; 1975 Sep; 2(7932):434-5. PubMed ID: 51240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent.
    Growdon JH; Young RR; Shahani BT
    Neurology; 1976 Dec; 26(12):1135-40. PubMed ID: 1086988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Utilization of levo-5-hydroxytryptophan in post-anoxic myoclonus].
    Rascol A; Guiraud-Chaumeil B; Laboucarie J; Montastruc JL; El-Hage W
    Therapie; 1978; 33(5):623-8. PubMed ID: 311085
    [No Abstract]   [Full Text] [Related]  

  • 18. Improvement of action myoclonus by an administration of 5-hydroxytryptophan and carbidopa in a child with muscular subsarcolemmal hyperactivity.
    Nakano K; Hayakawa T; Shishikura K; Ohsawa M; Suzuki H; Fukuyama Y
    Brain Dev; 1990; 12(5):516-20. PubMed ID: 2288384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations.
    Thal LJ; Sharpless NS; Wolfson L; Katzman R
    Ann Neurol; 1980 Jun; 7(6):570-6. PubMed ID: 6969054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonergic mechanisms in myoclonus.
    Growdon JH
    J Neural Transm Suppl; 1979; (15):209-16. PubMed ID: 290759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.